SCHEDULE 13G/A
Statement of Beneficial Ownership
NEKTAR THERAPEUTICS Filed Acc 0000921895-26-001397
Stakes reported in this filing
| Reporting person | Shares | Of the class |
|---|---|---|
| BVF PARTNERS L P/IL | 2,852,698 | 9.8% |
| BVF INC/IL | 2,852,698 | 9.8% |
| LAMPERT MARK N | 2,852,698 | 9.8% |
| BVF GP HOLDINGS LLC | 2,638,052 | 9.1% |
| BIOTECHNOLOGY VALUE FUND L P | 1,523,980 | 5.3% |
| BVF I GP LLC | 1,523,980 | 5.3% |
| BIOTECHNOLOGY VALUE FUND II LP | 1,114,072 | 3.9% |
| BVF II GP LLC | 1,114,072 | 3.9% |
| Biotechnology Value Trading Fund OS LP | 171,769 | 0.6% |
| BVF Partners OS Ltd. | 171,769 | 0.6% |
Members of a group can each report the same shares, so these rows overlap and don't add up.
Stake history · largest stake in each 13D and 13G
- 2026-11-10 SCHEDULE 13G · STATE STREET CORPORATION 5.2%
- 2026-09-28 SCHEDULE 13G/A · Two Seas Capital LP 9.8%
- 2026-08-14 SCHEDULE 13G/A · Two Seas Capital LP 9.1%
- 2026-08-14 SCHEDULE 13G/A · BVF PARTNERS L P/IL 7.1%
- 2026-07-31 SCHEDULE 13G · Vanguard Capital Management 5.17%
- 2026-07-29 SCHEDULE 13G · BlackRock, Inc. 7.8%
- 2026-05-15 SCHEDULE 13G/A · BVF PARTNERS L P/IL 9.8%
- 2026-05-06 SCHEDULE 13G/A · FMR LLC 15.0%
- 2026-04-17 SCHEDULE 13G · Two Seas Capital LP 6.8%
- 2026-03-27 SCHEDULE 13G/A · The Vanguard Group 0%
- 2026-03-06 SCHEDULE 13G · FMR LLC 11.1%
Loading xslSCHEDULE_13G_X02/primary_doc.xml…